The proposed trial into the use of LDN in Multiple Sclerosis is making progress. We have passed the second round of peer comment from outside experts and have now been invited to submit a full application to the Chief Scientists Office. This is a very positive step and indicates that the trial is viewed as being viable. We have several other hurdles to cross including gaining approval from the MHRA and ethics but things are well on there way and hopefully we will have secured funding by the time the conference takes place in April.

Share/Save/Bookmark